Printer Friendly

CHRISTOPHER K. MIRABELLI DEPARTS ISIS PHARMACEUTICALS TO HEAD BIOTECHNOLOGY START-UP

 CARLSBAD, Calif., June 29 /PRNewswire/ -- Isis Pharmaceuticals Inc. (NASDAQ: ISIP) today announced that Christopher K. Mirabelli, Ph.D., executive vice president of the company's research and preclinical development group, will resign, effective July 31, 1993, to become chairman and chief executive officer of Leukon, a biotechnology start-up in Boston. Mirabelli, 38, was co-founder of Isis.
 "My career and I have worked to a point at which I can lead a company. Leukon presented this opportunity for me," said Mirabelli. "I have been with Isis since the company's inception and have watched it mature into an exciting pharmaceutical company with a talented and diverse scientific staff. I can now leave the company with the comfort of knowing from a scientific and business perspective that Isis' success is assured. With my Isis experience, I feel confident that I am ready to lead a newly founded company."
 "Chris Mirabelli and I have worked together for more than 15 years," said Stanley T. Crooke, M.D., Ph.D., chairman, president and chief executive officer of Isis. "He is a talented scientist with much to contribute to the pharmaceutical industry. At Isis, we have assembled a strong, cohesive team which will continue the scientific research direction and progress of the company. Chris and I have worked together to assure a smooth transition and none of the rest of the Isis team will be leaving with him. Chris will be missed personally and professionally by us all, and we wish him the best of luck in his new endeavor."
 Isis Pharmaceuticals Inc., based in northern San Diego County, is engaged in the discovery and development of novel oligonucleotide-based human therapeutic compounds. Isis has a broad oligonucleotide research program which has resulted in multiple compounds in preclinical development. The company's first oligonucleotide-based drug, ISIS 2105, is currently in pivotal Phase II clinical trials.
 -0- 6/29/93
 /CONTACT: Jacqueline G. Siegel, Ph.D. of Isis Pharmaceuticals, (work) 619-931-9200, or (6:30-8:30 a.m. PDT) 619-929-2450; or Lorraine Ruff of Stoorza, Ziegaus & Metzger, (work) 619-236-1332, or (home) 619-755-5610, for Isis Pharmaceuticals/
 (ISIP)


CO: Isis Pharmaceuticals Inc.; Leukon ST: California IN: MTC SU: PER

MF-JL -- SD002 -- 6597 06/29/93 09:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 29, 1993
Words:365
Previous Article:MAIN ST. & MAIN INC. ANNOUNCES COMPLETION OF ACQUISITION OF FOUR T.G.I. FRIDAY'S RESTAURANTS
Next Article:NEW U.S. AND CANADA MOBILINK CELLULAR SERVICE ACTIVATED
Topics:


Related Articles
ISIS RECEIVES FDA APPROVAL TO BEGIN CLINICAL TRIALS ON ANTISENSE HPV DRUG
ISIS PHARMACEUTICALS DISCOVERS NEW BINDING TECHNIQUE
Isis Receives $10 Million Milestone Payment from Boehringer Ingelheim for Isis 2302
Isis To Collaborate With UCSF On Combinatorial Drug Discovery Through Biotechnology 'STAR' Grant
Mark Skaletsky Elected to Leukosite Board of Directors
Millennium Announces the Completion of LeukoSite and Millennium BioTherapeutics Mergers.
Millennium announces the completion of LeukoSite and Millennium BioTherapeutics mergers.
Isis license functional genomics patents to atugen.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters